OPCML, frequently inactivated in ovarian tumors, mediates its antitumor effect via binding to the extracellular domains of several important oncogenic receptor tyrosine kinases (RTK). This, in turn, leads to the downregulation of RTKs in tumor cells and results in significant inhibition of tumor growth. © 2012 American Association for Cancer Research.
CITATION STYLE
Wu, S. Y., & Sood, A. K. (2012). New roles opined for OPCML. Cancer Discovery, 2(2), 115–116. https://doi.org/10.1158/2159-8290.CD-11-0356
Mendeley helps you to discover research relevant for your work.